StockVS

M Evo Global Acquisition Corp II (MEVOU) 股票分析

金融服务

M Evo Global Acquisition Corp II

$10.10

+$0.04 (+0.40%)

最后更新: 2026年5月26日

价格走势

分析

公司概述

M Evo Global Acquisition Corp II is a specialized entity dedicated to executing business combination transactions, such as mergers, amalgamations, share exchanges, asset acquisitions, or reorganizations with one or more target businesses. The company operates within the Financial Services sector, specifically categorized under the industry of Shell Companies, which typically implies a structure designed to facilitate a merger with a private company before listing on a public exchange. Although the company was incorporated in 2025 and is headquartered in Farmers Branch, Texas, its current market cap is listed as N/A, and its annual revenue and employee count are also reported as N/A. The absence of defined market capitalization and revenue figures in the current data reflects the pre-business combination status typical of shell companies, indicating that the firm's valuation and operational scale are currently theoretical rather than based on historical financial performance or established earnings streams.

财务健康

The reported net income over the trailing twelve months stands at $-119,861, while both revenue and EBITDA figures are recorded as N/A. The significant negative net income in the absence of reported revenue highlights a cost structure where operating expenses, likely comprising legal, administrative, and listing fees, far exceed any generated income prior to a potential merger. Free cash flow is listed as N/A, which indicates that the company currently lacks the cash generation capacity associated with a mature operating business, relying instead on external capital sources for liquidity. Analysis of the three primary margins reveals that the gross margin, operating margin, and profit margin are all reported as 0.0%, a standard characteristic for shell companies that have not yet engaged in commercial transactions to generate sales. In terms of solvency, the company holds N/A in cash against a debt obligation of $10, resulting in a debt-to-equity ratio of 0.06. While the debt-to-equity ratio suggests a low leverage position relative to equity, the balance sheet's health is contingent on the N/A cash balance rather than operational cash flows. Furthermore, the current ratio is reported as 0.11, indicating that the company's current assets are significantly below its current liabilities, which points to potential short-term liquidity constraints typical for pre-SPAC entities. Return on Equity and Return on Assets are both listed as N/A, meaning that traditional metrics for assessing management effectiveness based on asset utilization or equity generation cannot yet be calculated due to the lack of a defined operating base.

估值评估

The trailing P/E ratio and forward P/E ratio are both listed as N/A, reflecting the company's status as a pre-earnings entity where standard earnings-based valuation multiples are not applicable. The price-to-book ratio is reported at -3340.00, a figure that indicates a severe market deviation from book value and suggests that the market is pricing the stock based on speculative potential rather than tangible asset backing. Similarly, the price-to-sales ratio and EV/EBITDA are listed as N/A, reinforcing that alternative valuation metrics relying on revenue or earnings multiples are currently unavailable for this asset. The stock has traded within a narrow 52-week range, with a high of $10.50 and a low of $10.01, though the specific current trading price relative to this range is not explicitly provided in the dataset. The beta value is listed as N/A, meaning that the stock's volatility relative to the broader market cannot be quantified with the available historical data. These valuation metrics collectively suggest that the asset is not being valued through traditional fundamental analysis but rather through market sentiment regarding its potential future business combination.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated recurring revenue streams to support growth rate calculations. Since the dividend yield and payout ratio are reported as N/A, the company does not currently distribute dividends to shareholders, instead retaining any available capital or relying on trust proceeds for future growth initiatives. This reinvestment strategy is typical for shell companies, which prioritize capital preservation and the execution of a merger over immediate income distribution to investors. Consequently, the overall growth and income profile for M Evo Global Acquisition Corp II is currently undefined, as the firm operates in a transitional phase where future performance is entirely dependent on the successful completion of a business combination transaction.

同行比较

M Evo Global Acquisition Corp II (MEVOU) 在壳公司行业运营。以下是其与市值最接近的同行的比较:

公司 代码 市值 市盈率
M Evo Global Acquisition Corp II MEVOU N/A N/A
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

壳公司行业平均市盈率为82.8倍。M Evo Global Acquisition Corp II的市盈率为N/A。

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于M Evo Global Acquisition Corp II

M Evo Global Acquisition Corp II focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2025 and is headquartered in Farmers Branch, Texas.

公司简介以英文显示。

关键指标

市值
N/A
市盈率
N/A
52周最高
$10.50
52周最低
$10.01
平均成交量
8.97K

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
NASDAQ
国家
United States